Clinical Trial Update: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RC48-ADC in HER2-overexpressed metastatic biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN